GeoVax Labs (NASDAQ:GOVX) Price Target Raised to $10.00

GeoVax Labs (NASDAQ:GOVX) had its price target increased by Noble Financial from $6.00 to $10.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have an outperform rating on the stock. Noble Financial also issued estimates for GeoVax Labs’ Q3 2024 earnings at ($1.61) EPS and Q4 2024 earnings at ($1.74) EPS.

A number of other research firms also recently weighed in on GOVX. HC Wainwright reaffirmed a buy rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Monday, August 12th. Roth Mkm began coverage on shares of GeoVax Labs in a research note on Tuesday, July 16th. They issued a buy rating and a $20.00 price target on the stock. Roth Capital raised shares of GeoVax Labs to a strong-buy rating in a research report on Tuesday, July 16th. Finally, EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a strong-buy rating in a research report on Tuesday, July 23rd. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of Buy and a consensus target price of $12.67.

GeoVax Labs Price Performance

Shares of NASDAQ:GOVX opened at $8.35 on Monday. The company’s fifty day moving average is $2.84 and its two-hundred day moving average is $2.24. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($1.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.57) by $0.58. The company had revenue of $0.30 million during the quarter. During the same quarter in the previous year, the business earned ($3.30) earnings per share. On average, equities research analysts forecast that GeoVax Labs will post -7.41 EPS for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC purchased a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned 91.38% of GeoVax Labs at the end of the most recent reporting period. 6.09% of the stock is owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.